Esophageal Cancer Treatment in India

India's thoracic oncology centres offer minimally invasive esophagectomy (MIE), neoadjuvant chemoradiation (CROSS protocol), and targeted therapy for esophageal squamous cell carcinoma and adenocarcinoma.

Get a Free Treatment Plan in 48 Hours

Send your reports — our specialists will review and send a personalised treatment plan and cost estimate.

📋 Get Free Consultation

Signs & Symptoms of Esophageal Cancer

  • Progressive difficulty swallowing (dysphagia)
  • Unintentional weight loss
  • Chest pain or pressure
  • Regurgitation of food
  • Chronic cough or hoarseness
  • Heartburn (for adenocarcinoma)

Treatment Options Available in India

  • Minimally invasive esophagectomy (MIE/VATS)
  • Ivor Lewis esophagectomy
  • CROSS protocol (carboplatin + paclitaxel + RT)
  • 5-FU + Cisplatin chemotherapy
  • HER2-targeted therapy (for adenocarcinoma)
  • Nivolumab immunotherapy (PD-L1+)
  • Endoscopic mucosal resection (early disease)

Why Treat Esophageal Cancer in India?

India offers world-class cancer care at a fraction of Western costs, with no compromise on quality or outcomes.

Cost ComparisonIndiaUSA
Esophageal Cancer Treatment (total)$6,000–$18,000$60,000–$180,000
Savings with India60–80% less than USA

Best Hospitals

  • Tata Memorial Hospital, Mumbai
  • Apollo Hospitals, Chennai
  • AIIMS, New Delhi
  • Fortis Memorial Research Institute, Gurugram
  • Kidwai Memorial Institute, Bangalore

Key Facts

  • India performs 2,000+ esophagectomies annually
  • MIE in India costs $8,000–$12,000 vs $60,000–$100,000 in USA
  • HER2 testing for esophageal adenocarcinoma done within 5 days
  • Post-operative mortality at top Indian centres: 2–4%

Frequently Asked Questions

Q: Can esophageal cancer be cured in India?

A: Stage I/II esophageal cancer achieves 40–60% 5-year survival with surgery. Neoadjuvant chemoradiation followed by esophagectomy improves this to 50–65%. Stage III/IV is managed with palliative intent, with immunotherapy extending survival significantly in PD-L1+ patients.

Related Cancer Types